- Home
- IMMP
IMMP
Immutep Limited
as 11-15-2024 4:00pm EST
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
| Founded: | 1987 | Country: | Australia |
| Employees: | N/A | City: | N/A |
| Market Cap: | 264.7M | IPO Year: | N/A |
| Target Price: | $8.50 | AVG Volume (30 days): | 106.2K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.58 - $3.34 | Next Earning Date: | 11-26-2024 |
| Revenue: | $2,563,302 | Revenue Growth: | 9.59% |
| Revenue Growth (this year): | -19.1% | Revenue Growth (next year): | 10.84% |
Latest Immutep Limited News
IMMP Breaking Stock News: Dive into IMMP Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Sector Update: Health Care Stocks Lower Thursday Afternoon
MT Newswires
3 days ago
Immutep Shares Rally Following Positive Phase 1 Trial Data of Efti Combination Therapy in Non-Small Cell Lung Cancer
GlobeNewswire
3 days ago
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
GlobeNewswire
3 days ago
Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting
Simply Wall St.
11 days ago
Immutep (ASX:IMM) shareholders have endured a 51% loss from investing in the stock three years ago
GlobeNewswire
19 days ago
Immutep Quarterly Activities Report Q1 FY25
GlobeNewswire
20 days ago
Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024
MT Newswires
a month ago
Immutep Completes Recruitment for Early-Stage Trial of IMP761, Advances to Dose Escalation
Compare IMMP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMMP Immutep Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.